Bath salts and synthetic cathinones: an emerging designer drug phenomenon.
Christopher L German, Annette E Fleckenstein, Glen R. Hanson
Life Sciences February 27, 2014 DOI: 10.1016/j.lfs.2013.07.023 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Keywords | Bath salts Designer drugs Mdpv Mephedrone Methylone Stimulants Synthetic cathinone |
| Key findings | The review indicates that synthetic cathinones, abused for effects similar to cocaine, MDMA, and amphetamines, act mainly by dysregulating central monoamine systems, which presumably underlies their behavioral effects and abuse liability. It also outlines their emergence as 'bath salts' products, their legal classification in Europe and the US, and discusses the benefits and drawbacks of that classification. |
Abstract
Synthetic cathinones are an emerging class of designer drugs abused for psychostimulant and hallucinogenic effects similar to cocaine, methylenedioxymethamphetamine (MDMA), or other amphetamines. Abuse of synthetic cathinones, frequently included in products sold as 'bath salts', became prevalent in early 2009, leading to legislative classification throughout Europe in 2010 and schedule I classification within the United States in 2011. Recent pre-clinical and clinical studies indicate that dysregulation of central monoamine systems is a principal mechanism of synthetic cathinone action and presumably underlie the behavioral effects and abuse liability associated with these drugs. This review provides insight into the development of synthetic cathinones as substances of abuse, current patterns of their abuse, known mechanisms of their action and toxicology, and the benefits and drawbacks of their classification.
Citations in the library
Cited by 17
- Neuropharmacology of New Psychoactive Substances (NPS): Focus on the Rewarding and Reinforcing Properties of Cannabimimetics and Amphetamine-Like Stimulants Frontiers in Neuroscience April 19, 2016
- Baths Salts, Spice, and Related Designer Drugs: The Science Behind the Headlines Journal of Neuroscience November 12, 2014
- Reports of Adverse Events Associated with Use of Novel Psychoactive Substances, 2017–2020: A Review Journal of Analytical Toxicology April 20, 2022
- Novel Psychoactive Substances—Recent Progress on Neuropharmacological Mechanisms of Action for Selected Drugs Frontiers in Psychiatry August 18, 2017
- The Pharmacological Profile of Second Generation Pyrovalerone Cathinones and Related Cathinone Derivative International Journal of Molecular Sciences July 31, 2021
and 12 more in the library
Cites 8
- Instability of the ecstasy market and a new kid on the block: mephedrone Journal of Psychopharmacology September 8, 2010
- The origin of MDMA (ecstasy) revisited: the true story reconstructed from the original documents* Addiction July 8, 2006
- Suspected and Confirmed Fatalities Associated With Mephedrone (4-Methylmethcathinone, “Meow Meow”) in the United Kingdom Journal of Clinical Psychopharmacology August 25, 2012
- Contrasting effects of d-methamphetamine, 3,4-methylenedioxymethamphetamine, 3,4-methylenedioxypyrovalerone, and 4-methylmethcathinone on wheel activity in rats Drug and Alcohol Dependence June 3, 2012
- Mephedrone, compared with MDMA (ecstasy) and amphetamine, rapidly increases both dopamine and 5-HT levels in nucleus accumbens of awake rats British Journal of Pharmacology May 26, 2011
and 3 more in the library